Sign In
Buy EDAP
EDAP TMS S.A Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.220 |
| EPS actual | -$0.240 |
| EPS Surprise | -9.09% |
| Revenue estimate | 16.586M |
| Revenue actual | 17.812M |
| Revenue Surprise | 7.39% |
| Release date | Mar 25, 2026 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.250 |
| EPS Surprise | -56.25% |
| Revenue estimate | 21.345M |
| Revenue actual | 21.909M |
| Revenue Surprise | 2.64% |
| Release date | Nov 06, 2025 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.150 |
| EPS Surprise | 42.31% |
| Revenue estimate | 21.28M |
| Revenue actual | 16.256M |
| Revenue Surprise | -23.61% |
| Release date | Aug 28, 2025 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.170 |
| EPS Surprise | 5.56% |
| Revenue estimate | 14.592M |
| Revenue actual | 18.89M |
| Revenue Surprise | 29.45% |
Last 4 Quarters for EDAP TMS S.A
Below you can see how EDAP performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 28, 2025 |
| Price on release | $1.82 |
| EPS estimate | -$0.180 |
| EPS actual | -$0.170 |
| EPS surprise | 5.56% |
| Date | Price |
|---|---|
| Aug 22, 2025 | $1.35 |
| Aug 25, 2025 | $1.37 |
| Aug 26, 2025 | $1.52 |
| Aug 27, 2025 | $1.58 |
| Aug 28, 2025 | $1.82 |
| Aug 29, 2025 | $2.26 |
| Sep 02, 2025 | $2.76 |
| Sep 03, 2025 | $2.75 |
| Sep 04, 2025 | $2.52 |
| 4 days before | 34.81% |
| 4 days after | 38.46% |
| On release day | 24.18% |
| Change in period | 86.67% |
| Release date | Nov 06, 2025 |
| Price on release | $1.99 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.150 |
| EPS surprise | 42.31% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $2.14 |
| Nov 03, 2025 | $2.00 |
| Nov 04, 2025 | $2.03 |
| Nov 05, 2025 | $2.08 |
| Nov 06, 2025 | $1.99 |
| Nov 07, 2025 | $2.02 |
| Nov 10, 2025 | $2.03 |
| Nov 11, 2025 | $2.02 |
| Nov 12, 2025 | $2.02 |
| 4 days before | -7.01% |
| 4 days after | 1.26% |
| On release day | 1.51% |
| Change in period | -5.84% |
| Release date | Mar 25, 2026 |
| Price on release | $3.71 |
| EPS estimate | -$0.160 |
| EPS actual | -$0.250 |
| EPS surprise | -56.25% |
| Date | Price |
|---|---|
| Mar 19, 2026 | $3.80 |
| Mar 20, 2026 | $3.61 |
| Mar 23, 2026 | $3.73 |
| Mar 24, 2026 | $3.91 |
| Mar 25, 2026 | $3.71 |
| Mar 26, 2026 | $3.77 |
| Mar 27, 2026 | $3.73 |
| Mar 30, 2026 | $3.62 |
| Mar 31, 2026 | $3.72 |
| 4 days before | -2.37% |
| 4 days after | 0.270% |
| On release day | 1.62% |
| Change in period | -2.11% |
| Release date | May 07, 2026 |
| Price on release | $4.16 |
| EPS estimate | -$0.220 |
| EPS actual | -$0.240 |
| EPS surprise | -9.09% |
| Date | Price |
|---|---|
| May 01, 2026 | $3.47 |
| May 04, 2026 | $3.34 |
| May 05, 2026 | $3.45 |
| May 06, 2026 | $3.60 |
| May 07, 2026 | $4.16 |
| May 08, 2026 | $4.13 |
| May 11, 2026 | $4.17 |
| May 12, 2026 | $4.08 |
| May 13, 2026 | $4.16 |
| 4 days before | 19.88% |
| 4 days after | 0% |
| On release day | -0.721% |
| Change in period | 19.88% |
EDAP TMS S.A Earnings Call Transcript Summary of Q1 2026
EDAP TMS reported a strong Q1 2026 with record total revenue of $17.8M driven by a 78% YoY increase in HIFU revenue to $11.6M. The quarter included 11 Focal One capital sales and 10 net placements, with notable U.S. academic and multi-system adoption (e.g., UPMC, Moffitt, Mass General Brigham). U.S. procedure volumes rose 53% YoY, and international momentum was strong—particularly in Europe (first French cash sale after national coverage for Focal One) and new placements across Latin America and Eastern Europe. The HIFI-2 study was highlighted as a major clinical milestone (71% of patients avoided hormone deprivation therapy at 30 months), supporting reimbursement and guideline recognition for salvage HIFU after radiation failure. Gross margin improved to 45.7% (HIFU margin 51.4%); operating loss widened to $7.4M and net loss was $9.1M ($0.24/sh). Inventory rose to support demand; cash was $15M at quarter end, and an approx. $14M tranche from the European Investment Bank was received in April. Management reiterated 2026 guidance: core HIFU revenue $50–54M and noncore $22–26M. Key near-term catalysts include AUA next week, Investor Day on June 1, continued indication expansion (endometriosis and BPH), and product/technology updates.
